Physician profile
Michael W Shore
NPI 1932100641
$3,103.16
in general payments reported to CMS, 2019-2025
16 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $366 · 2021: $441 · 2022: $471 · 2023: $580 · 2024: $468 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.38 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $613.70 | 2019-2022 | |
| Lundbeck LLC | $402.03 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.91 | 2022-2025 | Caplyta |
| Allergan, INC. | $301.96 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $264.27 | 2022-2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $255.47 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $231.63 | 2021-2025 | Rexulti |
| Abbvie INC. | $183.68 | 2021-2024 | Vraylar |
| Alkermes, INC. | $166.00 | 2021-2023 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $135.77 | 2022-2023 | Quviviq |
| Orexo US, INC. | $75.58 | 2019-2022 | |
| Shire North American Group INC | $39.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.02 | 2025 | Cobenfy |
| Corium, LLC | $16.66 | 2022 | |
| Indivior INC. | $11.19 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.